Cargando…

Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab

INTRODUCTION: IL-13 is the primary upregulated cytokine in atopic dermatitis (AD) skin and is the pathogenic mediator driving AD pathophysiology. Lebrikizumab, tralokinumab and cendakimab are therapeutic monoclonal antibodies (mAb) that target IL-13. METHODS: We undertook studies to compare in vitro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okragly, Angela J., Ryuzoji, Aya, Wulur, Isabella, Daniels, Montanea, Van Horn, Robert D., Patel, Chetan N., Benschop, Robert J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307934/ https://www.ncbi.nlm.nih.gov/pubmed/37310643 http://dx.doi.org/10.1007/s13555-023-00947-7

Ejemplares similares

Interleukin-33 Contributes Toward Loss of Tolerance by Promoting B-Cell-Activating Factor of the Tumor-Necrosis-Factor Family (BAFF)-Dependent Autoantibody Production
por: Rose, William A., et al.
Publicado: (2018)

Generation and Characterization of Torudokimab (LY3375880): A Monoclonal Antibody That Neutralizes Interleukin-33
por: Okragly, Angela J, et al.
Publicado: (2021)

Lebrikizumab in the personalized management of asthma
por: Thomson, Neil C, et al.
Publicado: (2012)

IL-33 released by alum is responsible for early cytokine production and has adjuvant properties
por: Rose II, William A., et al.
Publicado: (2015)

Profile of lebrikizumab and its potential in the treatment of asthma
por: Maselli, Diego Jose, et al.
Publicado: (2015)

Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis
por: Loh, Tiffany Y, et al.
Publicado: (2020)

Managing Atopic Dermatitis with Lebrikizumab – The Evidence to Date
por: Labib, Angelina, et al.
Publicado: (2022)

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
por: Bernardo, Diana, et al.
Publicado: (2023)

Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)
por: Szefler, Stanley J., et al.
Publicado: (2022)

Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis
por: Maher, Toby M., et al.
Publicado: (2021)

Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma
por: Nakamura, Yutaka, et al.
Publicado: (2017)

The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge
por: Scheerens, H, et al.
Publicado: (2014)

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial
por: Guttman-Yassky, Emma, et al.
Publicado: (2020)

Serum Interleukin-13 and Caspase 8 are Elevated in Prurigo Nodularis
por: JU, Teresa, et al.
Publicado: (2023)

Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials
por: Stein Gold, Linda, et al.
Publicado: (2023)

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies
por: Hanania, Nicola A, et al.
Publicado: (2015)

The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
por: Bashrahil, Bader, et al.
Publicado: (2023)

A randomized, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)
por: Austin, Cary D., et al.
Publicado: (2020)

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
por: Zhang, Lin, et al.
Publicado: (2021)

The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination
por: Benschop, Robert J., et al.
Publicado: (2022)

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere)
por: Simpson, Eric L., et al.
Publicado: (2023)

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
por: Paller, Amy S., et al.
Publicado: (2023)

Development and characterization of monoclonal antibodies specific for chicken interleukin-13 and their neutralizing effects in chicken primary monocytes
por: Chaudhari, Atul A., et al.
Publicado: (2019)

Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo
por: Ranganath, Sheila, et al.
Publicado: (2015)

Transplacental Passage of Interleukins 4 and 13?
por: Lim, Robert H., et al.
Publicado: (2009)

Clinical Investigation of the Role of Interleukin-4 and Interleukin-13 in the Evolution of Prostate Cancer
por: Goldstein, Robert, et al.
Publicado: (2011)

Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A
por: Liu, Ling, et al.
Publicado: (2016)

Circulating plasma IL-13 and periostin are dysregulated type 2 inflammatory biomarkers in prurigo nodularis: A cluster analysis
por: Parthasarathy, Varsha, et al.
Publicado: (2022)

The Effect of Mutations on Binding Interactions Between the SARS-CoV-2 Receptor Binding Domain and Neutralizing Antibodies
por: Barnes, Jonathan E., et al.
Publicado: (2021)

Neuroimmunology of the Interleukins 13 and 4
por: Mori, Simone, et al.
Publicado: (2016)

Active immunization with human interleukin-15 induces neutralizing antibodies in non-human primates
por: Rodríguez-Álvarez, Yunier, et al.
Publicado: (2016)

Binding affinity landscapes constrain the evolution of broadly neutralizing anti-influenza antibodies
por: Phillips, Angela M, et al.
Publicado: (2021)

The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies
por: Sok, Devin, et al.
Publicado: (2013)

Interleukin-13 in Asthma and Other Eosinophilic Disorders
por: Doran, Emma, et al.
Publicado: (2017)

The effect of interleukin-13 (IL-13) and interferon-γ (IFN-γ) on expression of surfactant proteins in adult human alveolar type II cells in vitro
por: Ito, Yoko, et al.
Publicado: (2010)

Differential effects of interleukin-13 and interleukin-6 on Jak/STAT signaling and cell viability in pancreatic β-cells
por: Russell, Mark A., et al.
Publicado: (2013)

Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus
por: Liu, Changbao, et al.
Publicado: (2007)

Antibody Neutralization of an Influenza Virus that Uses Neuraminidase for Receptor Binding
por: Gentles, Lauren E., et al.
Publicado: (2020)

Interleukin-25 Mediated Induction of Angiogenin-4 Is Interleukin-13 Dependent
por: Noor, Zannatun, et al.
Publicado: (2016)

Anti-Interleukin-22-Neutralizing Antibody Attenuates Angiotensin II-Induced Cardiac Hypertrophy in Mice
por: Ye, Jing, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c2lcjb6m13t8stnpsrnnh73crn